{"id":22408,"date":"2025-04-03T12:13:01","date_gmt":"2025-04-03T10:13:01","guid":{"rendered":"https:\/\/www.a-stw.com\/?p=22408"},"modified":"2025-04-03T12:13:37","modified_gmt":"2025-04-03T10:13:37","slug":"italy-life-sciences","status":"publish","type":"post","link":"https:\/\/www.a-stw.com\/en\/italy-life-sciences\/","title":{"rendered":"Italy\u2019s Numbers in Life Sciences: A Continuous Evolution"},"content":{"rendered":"\n

In 2022<\/strong>, the life sciences industry in Italy reached a production value of over \u20ac73 billion, with a value added exceeding \u20ac21 billion. This sector accounts for 3.9% of the value added of Italy\u2019s manufacturing industry, 1.8% of total employment, and 3.4% of investments in production. Moreover, in 2023<\/strong>, R&D investments in the pharmaceutical sector reached \u20ac2 billion, representing 17% of the sector\u2019s value added. A share significantly higher than the national average.<\/p>\n\n\n\n

Employment and Productivity in the Life Sciences Sector<\/strong><\/h2>\n\n\n\n

The share of workers employed in the life sciences sector in Italy stands at 1.7% of total manufacturing employment, ranking the country 15th in Europe<\/strong>. However, Italy stands out positively in terms of labor productivity in the sector, with an average productivity of \u20ac154.3 per employee\u2014just behind Germany (\u20ac164.9 per employee) and higher than France (\u20ac135.8 per employee) and Spain (\u20ac116.1 per employee).<\/p>\n\n\n\n

Investments in Research and Development<\/strong><\/h2>\n\n\n\n

Italian companies in the life sciences sector invest \u20ac13.1 per capita in research and development, which is less than France<\/strong> (\u20ac32.3 per capita), Spain <\/strong>(\u20ac17.1 per capita), and Germany <\/strong>(\u20ac66.5 per capita). However, public R&D investments in the life sciences sector in Italy amount to \u20ac14.0 per capita, placing the country 7th in Europe<\/strong>, although still behind Germany (\u20ac24.0 per capita) and Spain (\u20ac21.1 per capita).<\/p>\n\n\n\n

2024 Data<\/strong><\/h2>\n\n\n\n

As of now, definitive data for the year 2024 regarding the impact of Italian companies in the life sciences sector is not yet available. This delay is mainly due to the time required for the collection, processing, and publication of official statistical data, which often takes several months after the end of the reference year.<\/p>\n\n\n\n

Despite the lack of final data, some forecasts for 2024 indicate a positive trend for the life sciences sector in Italy. According to preliminary data, companies in the sector expect revenue growth during the current year, with 67% of respondents anticipating an increase between 5% and 20%<\/strong>. Organic expansion of the product portfolio is seen as the main strategy to drive innovation and growth, favoring internal strategies over acquisitions.<\/p>\n\n\n\n

Italy offers an excellent research and development ecosystem in the life sciences sector, with significant investments in both the pharmaceutical and biomedical segments. The country is at the forefront of research in several therapeutic areas, including oncology, neuroscience, and infectious diseases.<\/p>\n\n\n\n

Conclusions<\/strong><\/h2>\n\n\n\n

While awaiting official data for 2024, current forecasts and trends suggest sustained growth and a significant role for Italy in the life sciences sector at the European level. The optimism of companies, combined with robust investments in research and development, indicates a positive outlook for the sector\u2019s future in the country<\/strong>.<\/p>\n\n\n\n

Sources:<\/strong><\/p>\n\n\n\n